Quantitative measurement of human anti-HCV Core immunoglobulins on an electrical biochip platform

Kraus, Stefan; Kleines, Michael; Albers, Jörg; Blohm, Lars; Piechotta, G.; Püttmann, Christiane; Barth, Stefan; Nähring, Jörg; Nebling, Eric

doi:10.1016/j.bios.2010.03.026

Cited by 10 publications

(11 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1e). 10,35 Kraus et al 32 performed on-chip ELISA for hepatitis C (HCV) detection with signal enhancement technique. The target anti-HCV core immunoglobulin was captured on a gold electrode.…”

Section: Hepatitis (Hav Hbv Hcv)mentioning

confidence: 99%

Point-of-Care Microdevices for Blood Plasma Analysis in Viral Infectious Diseases

Yeh

Nisic

et al. 2014

Ann Biomed Eng

View full text Add to dashboard Cite

Each year, outbreaks of viral infections cause illness, disability, death, and economic loss. As learned from past incidents, the detrimental impact grows exponentially without effective quarantine. Therefore, rapid on-site detection and analysis are highly desired. In addition, for high-risk areas of viral contamination, close monitoring should be provided during the potential disease incubation period. As the epidemic progresses, a response protocol needs tobe rapidly implemented and the virus evolution fully tracked. For these scenarios, point-of-care microdevices can provide sensitive, accurate, rapid and low-cost analysis for a large population, especially in handling complex patient samples, such as blood, urine and saliva. Blood plasma can be considered as a mine of information containing sources and clues of biomarkers, including nucleic acids, immunoglobulin and other proteins, as well as pathogens for clinical diagnosis. However, blood plasma is also the most complicated body fluid. For targeted plasma biomarker detection or untargeted plasma biomarker discovery, the challenges can be as difficult as identifying a needle in a haystack. A useful platform must not only pursue single performance characteristics, but also excel at multiple performance parameters, such as speed, accuracy, sensitivity, selectivity, cost, portability, reliability, and user friendliness. Throughout the decades, tremendous progress has been made in point-of-care microdevices for viral infectious diseases. In this paper, we review fully integrated lab-on-chip systems for blood analysis of viral infectious disease.

show abstract

Section: Hepatitis (Hav Hbv Hcv)mentioning

confidence: 99%

Point-of-Care Microdevices for Blood Plasma Analysis in Viral Infectious Diseases

Yeh

Nisic

et al. 2014

Ann Biomed Eng

View full text Add to dashboard Cite

show abstract

“…The Core antigen was produced as previously described. 14 For NS3 and NS4A, a consensus sequence was generated by amino acid alignment (see supplementary material) and synthesized by Mr. Gene GmbH (Regensburg, Germany). The sequences were transferred to vector pET32a+ (Merck Chemicals, Nottingham, UK) using the enzymes NcoI-HF and NotI-HF (New England Biolabs GmbH, Frankfurt am Main, Germany) and expressed as thioredoxin (Trx)-fusion proteins in Escherichia coli strain Rosetta2 DE3 pLysS (Merck Chemicals).…”

Section: Preparation Of Antigensmentioning

confidence: 99%

“…The ELISA was carried out as previously described 14 of Trx-NS4A. After blocking with 1% (w/v) BSA, putative HCV-positive sera were diluted 1:200 in PBS and applied to the plate.…”

Section: Microtiter Plate Elisamentioning

confidence: 99%

“…The disposable silicon-based chips were manufactured on the industrial semiconductor production line at the Fraunhofer Institute for Silicon Technology, Itzehoe, Germany. [14][15][16] The new layout was based on chip dimensions of 8×10 mm and the production was modified to process 8-inch silicon wafers. The chips carried 16 unstructured gold electrode positions, each with a diameter of 350 µm.…”

Section: Biochip Fabrication and Integrationmentioning

confidence: 99%

“…12 An alternative to standard colorimetric enzyme-linked immunosorbent assays (ELISAs) is the cyclovoltammetric detection of HCV antigens 13 or the electrical biochip platform that uses "single electrode redox cycling" and detects anti-Core antibodies in the blood. 14 In combination with advanced lab-on-chip functionality, this technology has now been improved by the addition of two additional antigens to the biochip. Here we describe a demonstrator that integrates the HCV proteins Core, NS3, and NS4A, and measures an anti-HCV Ab response in diluted serum or whole blood samples in less than 15 minutes.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Rapid detection of different human anti-HCV immunoglobulins on electrical biochips

Blohm¹,

Püttmann²,

Holz³

et al. 2014

ANTI

Self Cite

View full text Add to dashboard Cite

The detection of hepatitis C virus (HCV) in the blood of patients is currently based on immunological assays (enzyme-linked immunosorbent assay [ELISA] and recombinant immunoblot assay) that use different HCV epitopes to detect anti-HCV antibodies, and these tests usually require laboratories and trained personnel. The ELISA-based systems are also time consuming. Portable diagnostic devices offering rapid test results would therefore be advantageous in the field of medical care. To facilitate the fast and reliable diagnosis of HCV, we used a miniaturized automated system based on a cartridge with an integrated electrical biochip for the decentralized detection of anti-HCV antibodies against the Core, NS3, and NS4A proteins. This system allows the detection of virus-specific antibodies in 2 µL of serum or whole blood within 15 minutes using an ELISA directly on a gold electrode array containing HCV proteins as the capture antigen. The sensitivity of this system is comparable with standard microtiter plate ELISAs, but the duration of the novel assay is 5%–6% that of standard ELISAs

show abstract

Platform Technologies for Molecular Diagnostics Near the Patient’s Bedside

Schumacher

Lüdecke

Ehrentreich‐Förster

et al. 2012

Molecular Diagnostics

View full text Add to dashboard Cite

It is believed Lab-on-Chip systems will become a mainstream technology within the next centuries. Especially because of new findings in molecular medicine and global trends such as the changing global population in third world countries and an ageing population in industrial countries, the need for fast and reliable diagnostics is rising tremendously. Hence, diagnostics have to become more frequently and more easily available. In this regard, technologies have to be found that enable the cost-effective production and hence an affordable price. In a joint-project between seven Fraunhofer institutes a Lab-on-Chip system was developed which consists of a credit-card-sized cartridge and a base station. The cartridges contain besides the reagents necessary for a specific assay also functionalities such as pumping or heating enabling a self-contained system without any fluidic interfaces, which tend to be error-prone. Because of the modularity of the system it is possible to integrate an optical sensor as well an electrochemical sensor into the cartridge. Hence, the system can be customized to serve the needs of the particular assays. This chapter will describe the system including generic design rules for such Lab-on-Chip systems, the development of these rules into a modular Lab-on-Chip system, the integration of biomedical assays, and the production possibility of this system.

show abstract

Quantitative measurement of human anti-HCV Core immunoglobulins on an electrical biochip platform

Cited by 10 publications

References 20 publications

Point-of-Care Microdevices for Blood Plasma Analysis in Viral Infectious Diseases

Point-of-Care Microdevices for Blood Plasma Analysis in Viral Infectious Diseases

Rapid detection of different human anti-HCV immunoglobulins on electrical biochips

Platform Technologies for Molecular Diagnostics Near the Patient’s Bedside

Contact Info

Product

Resources

About